Management of anticoagulant treatment in patients who need non-cardiac surgery

Abstract

The periprocedural management of anticoagulation in patients who require non-cardiac surgery is a common clinical problem due to the aging of the population associated with both an increase in the use of anticoagulants and a higher need for surgery. If surgery is needed in a patient on anticoagulant therapy, regardless of the drug used, it is necessary to consider the urgency of the surgical procedure and the balance between the thromboembolic risk related to the discontinuation of therapy and the hemorrhagic risk related to the surgical procedure itself. Finally, a topic still much discussed that derives from the combined evaluation of these factors is the possible indication of a bridge therapy (“bridging anticoagulation”) to limit the thromboembolic risk related to the discontinuation of treatment. The different strategies in patients under antivitamin K and direct oral anticoagulants are reviewed.

Keywords

Antivitamin K / direct oral anticoagulants / surgery / complications

References

[1] Spyropoulos AC,Omran H.Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy.Curr Med Res Opin2006;22:1109-22

[2] January CT,Calkins H.2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons.Circulation2019;140:e125-51

[3] Ickx BE.Perioperative management of patients receiving vitamin K antagonists.Can J Anaesth2006;53:S113-22

[4] Uotila L.The metabolic functions and mechanism of action of vitamin K.Scand J Clin Lab Invest1990;201:109-17

[5] Miller CS,Shimony A,Eisenberg MJ.Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.Am J Cardiol2012;110:453-60

[6] Gong IY.Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.Can J Cardiol2013;29:S24-33

[7] Spyropoulos AC,Dunn AS.REGIMEN InvestigatorsClinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.J Thromb Haemost2006;4:1246-52

[8] Douketis JD,Spencer FA.Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines.Chest2012;141:e326S-50S PMCID:PMC3278059

[9] Douketis JD.Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach.Blood2011;117:5044-9

[10] Woods K,Kathirgamanathan K,Crowther MA.Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin.J Thromb Thrombolysis2007;24:93-7

[11] Rechenmacher SJ.Bridging anticoagulation: primum non nocere.J Am Coll Cardiol2015;66:1392-403

[12] Moores TS,Cattell AE,Roberts PJ.Preoperative warfarin reversal for early hip fracture surgery.J Orthop Surg (Hong Kong)2015;23:33-6

[13] Dentali F,Giorgi Pierfranceschi M.Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis.Thromb Haemost2011;106:429-38

[14] Burbury KL,Snooks B,Westerman DA.Short-term warfarin reversal for elective surgery-using low-dose intravenous vitamin K: safe, reliable and convenient*.Br J Haematol2011;154:626-34

[15] Bhatia M,Parihar S.An audit of the role of vitamin K in the reversal of International Normalised Ratio (INR) in patients undergoing surgery for hip fracture.Ann R Coll Surg Engl2010;92:473-6 PMCID:PMC3182787

[16] Heidbuchel H,Alings M.Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.Europace2015;17:1467-507

[17] Lai A,Galloway SW.Perioperative management of patients on new oral anticoagulants.Br J Surg2014;101:742-9

[18] Viktil KK,Ranhoff AH.Serum concentrations and elimination rates of direct-acting oral anticoagulants (DOACs) in older hip fracture patients hospitalized for surgery: a pilot study.Drugs Aging2019;36:65-71

[19] Steffel J,Antz M.External reviewers2021 European heart rhythm association practical guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.Europace2021;23:1612-76

[20] van Ryn J,Haertter S.Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.Thromb Haemost2010;103:1116-27

[21] Eikelboom JW,van Ryn J.Idarucizumab: the antidote for reversal of dabigatran.Circulation2015;132:2412-22

[22] Eerenberg ES,Sijpkens MK,Buller HR.Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.Circulation2011;124:1573-9

[23] Marlu R,Paris A,Cracowski JL.Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.Thromb Haemost2012;108:217-24

[24] Pollack CV Jr,Eikelboom J.Idarucizumab for dabigatran reversal.N Engl J Med2015;373:511-20

[25] Siegal DM,Connolly SJ.Andexanet alfa for the reversal of factor Xa inhibitor activity.N Engl J Med2015;373:2413-24